These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22487079)

  • 21. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children.
    Zucchini S; Scipione M; Balsamo C; Maltoni G; Rollo A; Molinari E; Mangoni L; Cicognani A
    Diabetes Technol Ther; 2011 Dec; 13(12):1187-93. PubMed ID: 21854193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
    Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB
    Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
    Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump.
    González de Buitrago Amigo J; González García A; Díaz Fernández P; Fernández Llamas M; Tejado Bravo ML; de Nicolás Jiménez JM; Ferrer Lozano M
    An Pediatr (Engl Ed); 2021 Nov; 95(5):321-329. PubMed ID: 34645579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
    Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
    Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
    Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
    Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous subcutaneous insulin infusion pump treatment in children with type 1 diabetes mellitus.
    Liberatore R; Perlman K; Buccino J; Artiles-Sisk A; Daneman D
    J Pediatr Endocrinol Metab; 2004 Feb; 17(2):223-6. PubMed ID: 15055358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Nov; 39(11):2019-2025. PubMed ID: 27612500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
    Hirsch IB; Abelseth J; Bode BW; Fischer JS; Kaufman FR; Mastrototaro J; Parkin CG; Wolpert HA; Buckingham BA
    Diabetes Technol Ther; 2008 Oct; 10(5):377-83. PubMed ID: 18715214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump.
    Halvorson M; Carpenter S; Kaiserman K; Kaufman FR
    J Pediatr; 2007 Jan; 150(1):103-105.e1. PubMed ID: 17188626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of sensor-augmented pump therapy with predictive low-glucose management on hypoglycemia and glycemic control in patients with type 1 diabetes mellitus: 1-year follow-up.
    Gómez AM; Henao DC; Taboada LB; Leguizamón G; Rondón MA; Muñoz OM; García-Jaramillo MA; León Vargas FM
    Diabetes Metab Syndr; 2019; 13(4):2625-2631. PubMed ID: 31405686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiological factors influencing diabetes control in type 1 diabetes children with insulin pumps from diagnosis.
    Piechowiak K; Szypowska A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3086. PubMed ID: 30325106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-related differences in metabolic response to continuous subcutaneous insulin infusion in pre-pubertal and pubertal children with Type 1 diabetes mellitus.
    Rabbone I; Bobbio A; Berger K; Trada M; Sacchetti C; Cerutti F
    J Endocrinol Invest; 2007 Jun; 30(6):477-83. PubMed ID: 17646722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
    Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
    Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world outcomes of insulin pump compared to injection therapy in a population-based sample of children with type 1 diabetes.
    Burckhardt MA; Smith GJ; Cooper MN; Jones TW; Davis EA
    Pediatr Diabetes; 2018 Dec; 19(8):1459-1466. PubMed ID: 30129154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The influence of long-term therapy with the insulin pump (CSII) in patients with type 1 diabetes mellitus on metabolic compensation and on the incidence of hypoglycaemia. Comparison with intensified conventional insulin therapy (MDI)].
    Olsovský J; Beránek M
    Vnitr Lek; 2007 Jun; 53(6):637-45. PubMed ID: 17702123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry.
    Cohen O; Körner A; Chlup R; Zoupas CS; Ragozin AK; Wudi K; Bartaskova D; Pappas A; Niederland T; Taybani Z; Barák L; Vazeou A;
    J Diabetes Sci Technol; 2009 Jul; 3(4):804-11. PubMed ID: 20144331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.